| Name | Title | Contact Details |
|---|---|---|
Farid Shenassa |
Chief Technology Officer | Profile |
Larry Newfield |
Vice President Information Technology Systems Management and Security Compliance | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Explore Repslys retail execution platform and discover solutions for merchandising, field sales, and promotion execution. Learn how your field team can work smarter with Repsly today!
AR FortuneIT, Inc. is a Jersey City, NJ-based company in the Software and Internet sector.
DFINITY is building an open, decentralized compute platform designed to host the next generation of software and services with vastly improved performance and governance.
Reduce the frequency and impact of breaches by addressing the source - human risk. Orchestrate human risk through proactive security controls, contextual influence and intelligent investment analysis.